1. Israel Stocks

  2. •

    Healthcare

  3. •

    Medical - Distribution
Novolog (Pharm-Up 1966) Ltd

Novolog (Pharm-Up 1966) Ltd

NVLG.TA
Novolog (Pharm-Up 1966) LtdIL flagTel Aviv Stock Exchange
75.00
ILA
-0.40
- -
383.16MMarket Cap

Total Valuation

Novolog (Pharm-Up 1966) Ltd carries a market capitalization of 383.16M, placing it among publicly traded companies globally. Its enterprise value stands at 51.11B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Market Cap383.16M
Enterprise Value51.11B

Share Statistics

Novolog (Pharm-Up 1966) Ltd currently has 510.87M shares outstanding.

Shares Outstanding510.87M
Owned by Insiders (%)N/A
Owned by Institutions (%)N/A

Valuation Ratios

Novolog (Pharm-Up 1966) Ltd trades at a trailing price-to-earnings ratio of 14,412.36. The price-to-sales ratio is 28.32, and the price-to-book ratio stands at 10,000.36.

PE Ratio14,412.36
PS Ratio28.32
PB Ratio10,000.36
P/TBV Ratio1,240.39
P/FCF Ratio227.00
P/OCF Ratio298.92

Enterprise Valuation

On an enterprise value basis, Novolog (Pharm-Up 1966) Ltd trades at an EV/EBITDA multiple of 1,816.18 and an EV/FCF ratio of 211.20. The EV/Sales ratio of 28.33 reflects the premium investors are willing to pay for the company's revenue stream, while the EV/EBIT multiple of 1,816.18 provides insight into valuation relative to core operating earnings.

EV / Sales28.33
EV / EBITDA1,816.18
EV / EBIT1,816.18
EV / FCF211.20

Financial Position

Novolog (Pharm-Up 1966) Ltd maintains a current ratio of 0.94, meaning it holds 0.9x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 47.90, indicating elevated leverage, while an interest coverage ratio of 1.28 demonstrates limited ability to service its debt obligations.

Current Ratio0.94
Quick Ratio0.09
Debt / Equity47.90
Debt / EBITDA6.26
Interest Coverage1.28

Financial Efficiency

Novolog (Pharm-Up 1966) Ltd posts a return on equity of 69.39 and a return on invested capital of 3.84.

Return on Equity (ROE)69.39
Return on Assets (ROA)0.13
Return on Invested Capital (ROIC)3.84
Return on Capital Employed (ROCE)10.24
Revenue Per EmployeeN/A
Employee CountN/A
Inventory Turnover4.80

Taxes

Over the trailing twelve months, Novolog (Pharm-Up 1966) Ltd has paid 727,000.00 in income taxes, reflecting an effective tax rate of 22.99.

Income Tax727,000.00
Effective Tax Rate22.99

Stock Price Statistics

Novolog (Pharm-Up 1966) Ltd's stock has declined approximately -45.01466% over the past 52 weeks. The 50-day moving average sits at 85.01, while the 200-day moving average is 112.37.

Beta (5Y)N/A
52-Week Price Change-45.01466%
50-Day Moving Average85.01
200-Day Moving Average112.37
Average Volume (20 Days)N/A

Income Statement

Over the trailing twelve months, Novolog (Pharm-Up 1966) Ltd generated 1.80B in revenue and converted that into 3.55M in net income, yielding earnings per share of 0.01. EBITDA reached 28.14M, while operating income came in at 28.14M.

Revenue1.80B
Gross Profit137.00M
Operating Income28.14M
Pretax Income3.16M
Net Income3.55M
EBITDA28.14M
EBIT28.14M
Earnings Per Share (EPS)0.01

Balance Sheet

Novolog (Pharm-Up 1966) Ltd holds 163.20M in cash and equivalents against 176.20M in total debt, resulting in a net debt position of -163.20M. Total book value stands at 5.11M, with working capital of -119.38M providing operational flexibility.

Cash & Cash Equivalents163.20M
Total Debt176.20M
Net Debt-163.20M
Equity (Book Value)5.11M
Book Value Per Share0.01
Working Capital-119.38M

Cash Flow

Novolog (Pharm-Up 1966) Ltd produced 170.92M in operating cash flow over the past twelve months. After subtracting -54.15M in capital expenditures, free cash flow totaled 116.77M - equivalent to 0.23 per share.

Operating Cash Flow170.92M
Capital Expenditures-54.15M
Free Cash Flow116.77M
FCF Per Share0.23

Margins

Novolog (Pharm-Up 1966) Ltd operates with a gross margin of 7.59, reflecting its pricing power and cost economics. The operating margin of 1.56 and net profit margin of 0.20 provide insight into operational efficiency.

Gross Margin7.59
Operating Margin1.56
Pretax Margin0.18
Profit Margin0.20
EBITDA Margin1.56

Dividends & Yields

The company's payout ratio of 581.90 indicates the proportion of earnings distributed to shareholders.

Dividend Per Share0.04
Dividend YieldN/A
Payout Ratio581.90
Shareholder Yield0.14
FCF Yield0.44

Scores

Novolog (Pharm-Up 1966) Ltd posts an Altman Z-Score of 15.60, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.

Altman Z-Score15.60